Hangzhou Lifereal Biotechnology Secures Tens of Millions RMB in Series A Funding Led by Leading Diagnostics Company and Huagai Capital

VCBeat (WeChat ID: vcbeat) has learned that Hangzhou Suizhen Biotechnology Co., Ltd. has officially completed its Series A financing round, raising tens of millions of RMB. The investment was jointly made by a well-known listed diagnostics company and Huagai Capital.

Suizhen Biotechnology, established in September 2011, has been dedicated to the research, development, and manufacturing of products for life sciences and clinical diagnostics. The company has completed the development of its series of fully automated, integrated molecular diagnostic instruments and is committed to providing customers with cost-effective clinical diagnostic solutions. Regulatory approval processes for these products are proceeding in an orderly manner. Meanwhile, addressing scientific research needs in the life sciences, Suizhen provides high-quality research instruments and equipment bearing the hallmark of “Intelligent Manufacturing in China” to domestic and international clients, underpinned by advanced concepts, design, and utmost reliability. Its products comply with RoHS standards and have obtained CE certification. The company also offers OEM/ODM collaboration services tailored to customer requirements.

Leveraging Zhejiang University’s resource advantages and its team’s extensive experience in the R&D of high-end instruments and equipment, Suizhen Biology has successfully developed a range of patented life science instruments and clinical diagnostic devices. The company operates a 2,000-square-meter production base in Hangzhou Future Sci-Tech City and has established extensive business channels overseas. Its fully automated, integrated clinical diagnostic equipment has been fully developed and is poised for market launch. Previously, Suizhen Biology secured investment from YuanSheng Venture Capital.

This strategic financing round involves partnering with a well-known domestic listed diagnostics company. By leveraging complementary strengths, the collaboration aims to gradually translate product advantages into market advantages, serve the national health strategy, and contribute to the widespread adoption of domestically produced molecular diagnostic products.

Mr. Zhao Huai, Founder of Suizhen Biotech, stated, “We sincerely appreciate the trust placed in Suizhen Biotech and our team by Industrial Capital and Huagai Capital. The prospects for the application of molecular diagnostic products in China are vast, with many areas still underexploited. We are committed to working alongside industry peers to jointly enhance the technological standards of domestically produced molecular diagnostic products, particularly instruments and equipment, thereby providing customers with a series of molecular diagnostic solutions that are user-friendly, cost-effective, and high-performing. Our vision is to uncover the truth of life and safeguard public health, striving together to establish Suizhen Biotech as a leading enterprise in China’s molecular diagnostics sector.”

Mr. Lin Yi, Managing Partner of Yuansheng Ventures, stated, “We are deeply grateful that Suizhen Biology has gained the recognition of Industrial Capital and Huagai Capital. For many years, we have remained committed to our original mission of identifying and nurturing outstanding domestic and international teams, with the responsibility of meeting public health diagnostic needs. We strive to be the initiators and guardians of exceptional teams. Dr. Zhao Huai has nearly two decades of experience in R&D and sales on the front lines of the molecular diagnostics industry, accumulating extensive industry expertise. We look forward to this collaboration between Suizhen Biology and Industrial Capital driving Suizhen Biology to more rapidly and effectively refine its diagnostic product portfolio, achieving new heights of success.”